Why the study?
Comparison of different anticoagulants in blood management and complications with tranexamic acid in total hip arthroplasty is unclear.
Do different anticoagulants (nadroparin, enoxaparin, rivaroxaban) affect hidden blood loss differently in patients undergoing total hip arthroplasty after tranexamic acid?
Do different anticoagulants (nadroparin, enoxaparin, rivaroxaban) affect hidden blood loss differently in patients undergoing total hip arthroplasty after tranexamic acid?
Nadroparin, enoxaparin, and rivaroxaban show similar efficacy and safety regarding blood loss and complications when used after tranexamic acid in total hip arthroplasty.
Answers are grounded in this paper and cite their sources.
Clinicians may select among these anticoagulants post-TXA in THA without differential blood loss concerns; confirms comparable safety in this RCT.
Comparison of different anticoagulants in blood management and complications with tranexamic acid (TXA) in total hip arthroplasty (THA) is unclear. Our aim was to compare the efficacy and safety among receiving nadroparin calcium, enoxaparin sodium or rivaroxaban after TXA in THA.150 patients undergoing primary unilateral THA were received 15 mg/kg intravenous TXA (IV-TXA) before skin incision, followed by 1 of nadroparin calcium (Group A), enoxaparin sodium (Group B), or rivaroxaban (Group C) randomly during hospitalization. The primary outcome was hidden blood loss (HBL). Other outcomes such as the maximum hemoglobin (Hb) drop, total blood loss (TBL), the volume of drainage, transfusion rate, length of hospital stay (LOS), and complications were also compared.There were no statistically significant differences in HBL, the maximum hemoglobin (Hb) drop, transfusion rate, and complications among 3 groups. LOS was significantly higher for patients in Group B than Group A (P = .026). Neither deep venous thrombosis (DVT) nor pulmonary embolism (PE) occurred in any group.There were no differences in efficacy and safety in patients undergoing THA receiving nadroparin calcium, enoxaparin sodium, or rivaroxaban after anti-fibrinolysis with TXA.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: